Biblio

T. Kondo, Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., Takahashi, K., Asaka, I., Aoi, T., Watanabe, A., Watanabe, K., Kadoya, C., Nakano, R., Watanabe, D., Maruyama, K., Hori, O., Hibino, S., Choshi, T., Nakahata, T., Hioki, H., Kaneko, T., Naitoh, M., Yoshikawa, K., Yamawaki, S., Suzuki, S., Hata, R., Ueno, S. - I., Seki, T., Kobayashi, K., Toda, T., Murakami, K., Irie, K., Klein, W. L., Mori, H., Asada, T., Takahashi, R., Iwata, N., Yamanaka, S., and Inoue, H., “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.

C. E. Fischer, Qian, W., Schweizer, T. A., Millikin, C. P., Ismail, Z., Smith, E. E., Lix, L. M., Shelton, P., and Munoz, D. G., “Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 1, pp. 283-95, 2016.

R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.

R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H., “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.

V. Bonet-Costa, Herranz-Pérez, V., Blanco-Gandía, M. C., Mas-Bargues, C., Inglés, M., Garcia-Tarraga, P., Rodriguez-Arias, M., Miñarro, J., Borras, C., Garcia-Verdugo, J. Manuel, and Viña, J., “Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 701-11, 2016.

N. Pierrot, Lhommel, R., Quenon, L., Hanseeuw, B., Dricot, L., Sindic, C., Maloteaux, J. - M., Octavea, J. - N., and Ivanoiu, A., “Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 271-6, 2016.

P. Pastor, Moreno, F., Clarimón, J., Ruiz, A., Combarros, O., Calero, M., de Munain, A. López, Bullido, M. J., de Pancorbo, M. M., Carro, E., Antonell, A., Coto, E., Ortega-Cubero, S., Hernandez, I., Tárraga, L., Boada, M., Lleo, A., Dols-Icardo, O., Kulisevsky, J., Vázquez-Higuera, J. Luis, Infante, J., Rábano, A., Fernández-Blázquez, M. Ángel, Valentí, M., Indakoetxea, B., Barandiarán, M., Gorostidi, A., Frank-García, A., Sastre, I., Lorenzo, E., Pastor, M. A., Elcoroaristizabal, X., Lennarz, M., Maier, W., Rámirez, A., Serrano-Ríos, M., Lee, S. E., and Sánchez-Juan, P., “MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium.”, J Alzheimers Dis, vol. 49, no. 2, pp. 343-52, 2016.

D. J. Quintana-Hernández, Miró-Barrachina, M. T., Ibáñez-Fernández, I. J., Del Pino, A. Santana-, Quintana-Montesdeoca, M. P., de Vera, B. Rodríguez, Morales-Casanova, D., Pérez-Vieitez, M. Del Carmen, Rodríguez-García, J., and Bravo-Caraduje, N., “Mindfulness in the Maintenance of Cognitive Capacities in Alzheimer's Disease: A Randomized Clinical Trial.”, J Alzheimers Dis, vol. 50, no. 1, pp. 217-32, 2016.

N. Dermody, Hornberger, M., Piguet, O., Hodges, J. R., and Irish, M., “Prospective Memory Impairments in Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia: Clinical and Neural Correlates.”, J Alzheimers Dis, vol. 50, no. 2, pp. 425-41, 2016.

M. Ibarria, Alegret, M., Valero, S., Morera, A., Guitart, M., Cañabate, P., Moreno, M., Lara, S., Diego, S., Hernández, J., Tantinyá, N., Vera, M., Hernandez, I., Becker, J. T., Ruiz, A., Boada, M., and Tárraga, L., “Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.

A. Dodich, Cerami, C., Crespi, C., Canessa, N., Lettieri, G., Iannaccone, S., Marcone, A., Cappa, S. F., and Cacioppo, J. T., “Differential Impairment of Cognitive and Affective Mentalizing Abilities in Neurodegenerative Dementias: Evidence from Behavioral Variant of Frontotemporal Dementia, Alzheimer's Disease, and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1011-22, 2016.

F. Kumfor, Teo, D., Miller, L., Lah, S., Mioshi, E., Hodges, J. R., Piguet, O., and Irish, M., “Examining the Relationship Between Autobiographical Memory Impairment and Carer Burden in Dementia Syndromes.”, J Alzheimers Dis, vol. 51, no. 1, pp. 237-48, 2016.

A. Manousopoulou, Saito, S., Yamamoto, Y., Al-Daghri, N. M., Ihara, M., Carare, R. O., and Garbis, S. D., “Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 51, no. 2, pp. 333-8, 2016.

J. Kida, Nemoto, K., Ikejima, C., Bun, S., Kakuma, T., Mizukami, K., and Asada, T., “Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.”, J Alzheimers Dis, vol. 51, no. 2, pp. 405-15, 2016.

B. Ongali, Nicolakakis, N., Tong, X. - K., Aboulkassim, T., Imboden, H., and Hamel, E., “Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1183-95, 2016.

Y. Ling Chai, Yeo, H. Kai- Hui, Wang, J., Hilal, S., Ikram, M. Kamran, Venketasubramanian, N., Wong, B. - S., and Chen, C. Li- Hsian, “Apolipoprotein ɛ4 is Associated with Dementia and Cognitive Impairment Predominantly Due to Alzheimer's Disease and Not with Vascular Cognitive Impairment: A Singapore-Based Cohort.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1111-8, 2016.

A. Medoro, Bartollino, S., Mignogna, D., Passarella, D., Porcile, C., Pagano, A., Florio, T., Nizzari, M., Guerra, G., Di Marco, R., Intrieri, M., Raimo, G., and Russo, C., “Complexity and Selectivity of γ-Secretase Cleavage on Multiple Substrates: Consequences in Alzheimer's Disease and Cancer.”, J Alzheimers Dis, vol. 61, no. 1, pp. 1-15, 2018.

N. Iwahara, Hisahara, S., Kawamata, J., Matsumura, A., Yokokawa, K., Saito, T., Fujikura, M., Manabe, T., Suzuki, H., Matsushita, T., Suzuki, S., and Shimohama, S., “Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1235-1247, 2017.

W. H. Bouvy, Kuijf, H. J., Zwanenburg, J. J. M., Koek, H. L., L Kappelle, J., Luijten, P. R., M Ikram, K., and Biessels, G. Jan, “Abnormalities of Cerebral Deep Medullary Veins on 7 Tesla MRI in Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease: A Pilot Study.”, J Alzheimers Dis, vol. 57, no. 3, pp. 705-710, 2017.

Y. Hasegawa, Toyama, K., Uekawa, K., Ichijo, H., and Kim-Mitsuyama, S., “Role of ASK1/p38 Cascade in a Mouse Model of Alzheimer's Disease and Brain Aging.”, J Alzheimers Dis, vol. 61, no. 1, pp. 259-263, 2018.

A. Dodich, Cerami, C., Cappa, S. F., Marcone, A., Golzi, V., Zamboni, M., Giusti, M. Cristina, and Iannaccone, S., “Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers.”, J Alzheimers Dis, vol. 61, no. 2, pp. 761-772, 2018.

Main menu

User Top Menu

Pages

You are here

Biblio

Pages